Orexigen Therapeutics Inc (OREX)

3.12
NASDAQ : Health Care
Prev Close 3.09
Day Low/High 2.82 / 3.13
52 Wk Low/High 1.65 / 5.70
Avg Volume 182.40K
Exchange NASDAQ
Shares Outstanding 15.23M
Market Cap 47.05M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Orexigen Therapeutics Announces Publication Of Contrave® (naltrexone HCl And Bupropion HCl Extended-release Tablets) Real-World Study Results In

Orexigen Therapeutics Announces Publication Of Contrave® (naltrexone HCl And Bupropion HCl Extended-release Tablets) Real-World Study Results In "Obesity"

-- IGNITE study showed Contrave combined with a commercially-available weight loss program yielded nearly 10 percent body weight loss that persisted for 78 weeks --

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

Here's a technical look at how to trade several under-$10 stocks that are poised for breakouts.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under -$10 stocks are poised to breakout and trade higher from current levels.

Orexigen Announces South Korean Approval Of Contrave® (naltrexone HCI And Bupropion HCI Extended-Release) Monotherapy For Weight Management In Overweight Or Obese Adult Patients

Orexigen Announces South Korean Approval Of Contrave® (naltrexone HCI And Bupropion HCI Extended-Release) Monotherapy For Weight Management In Overweight Or Obese Adult Patients

Orexigen has shipped the first order of Contrave tablets to partner Kwang Dong in anticipation of a commercial launch later this quarter